Life Sciences Archive » September, 2025

Life Sciences - September, 2025

283 articles

• McKinsey Trims Endo Suit But Can't Nix Indemnification Claim
• 3rd Circ. Parses 'Could' And 'Would' In Lipitor Lawsuit
• Biogen Told To Pay Genentech $88M After IP Royalties Mistrial
• 4 Federal Circuit Clashes To Watch In October
• Blue Cross Insurers Sanctioned For 2-Year Discovery Drawout
• HHS Moves To Suspend Harvard From Funding
• Judge Freezes Chinese Cos.' Assets In X-Ray IP Suit
• Hospital Urges Justices To Review 7th Circ. Medicaid Ruling
• Pharma Co. Asks Judge To Toss 'Vague' Investor Class Action
• Junior Attys Must Beware Of 5 Common Legal Brief Mistakes
• Supreme Court Considers 7 Patent Petitions
• Pfizer Says Drugmaker Moving Too Early On Arthritis Generic
• Tribe Drops Price-Fixing Suit Against Drugmakers, PBMs
• Honeywell Says Ex-GC's Age Bias Suit Belongs Only In China
• CTA Could Face Second Ill. Jury Over Vaccine Bias Allegations
• House GOP Lawmakers Back ITC Import Ban Won By Oura
• No New Trial In Eyedrop TM Case, But Damages Cut To $11M
• 6th Circ. Won't Revive Software Development IP Case
• Terumo Secures $5M Cost Award After Beating Cancer Claims
• State AGs, Not Local Officials, Should Lead Public Litigation
• Catching Up With Delaware's Chancery Court
• Stewart Keeps Discretion Duty As Squires Takes On RPIs, AI
• Semler Scientific, Bard To Pay $37M To End FCA Claims
• Judge Criticizes Push For Harsher Sentence In CytoDyn Case
• CareDx Asks 3rd Circ. To Rethink $45M False Ad Case
• Inotiv Inks $8.75M Investor Deal Over Animal Welfare Claims
• Bayer Investors Seek Final OK Of $38M Settlement, Atty Fees
• Illumina And Grail Nix Investor Suit Over Failed Deal, For Now
• Cellectis, AstraZeneca Face IP Suit From Cell Engineering Co.
• DC Circ. Won't Stop FDA From Approving Entresto Generic
• Chemical Plant Spat Must Unfold In NY, NC Court Is Told
• High Court Pauses Distribution Of $4B Foreign Aid
• Trump Announces 100% Tariff On Drug Imports Starting Oct. 1
• Taxation With Representation: De Brauw, Hengeler Mueller
• 3rd Circ. Clarifies Ch. 11 3rd-Party Liability Scope Post-Purdue
• Texas Suit Marks Renewed Focus On Service Kickback Theory
• Power To The Paralegals: How And Why Training Must Evolve
• COVID-19 Orders Could Save Embryo Loss Case, Court Hears
• Judge Plans To Let ITC Take Lead In Apple Watch Patent Fight
• Perrigo Mostly Beats US In $163M Tax Refund Dispute
• MiMedx, FDA Ordered To Rework Args In Wound Care Case
• Pa. High Court Backs Two-Lab Rule For Medical Pot Products
• Dr. Reddy's To Keep Generic Cancer Drug Off Market Until 2030
• AstraZeneca Asks High Court To 'Unscramble' Drug Price Law
• Labcorp Workers Balk At Paying For Expert's Biz Class Airfare
• Playing Softball Makes Me A Better Lawyer
• 5 Years In, COVID-19 Fraud Enforcement Landscape Is Shifting
• SmartLabs Accused Of Dodging Rent On Cambridge Lab
• Depo-Provera MDL Plaintiff Numbers Balloon To 1,300
• Fed. Circ. In August: A Framework For AIA Derivation Disputes
• In-House Life Sciences Lawyer Joins WilmerHale In Boston
• Families Cite Trump In Bid To Revive Tylenol Autism Claims
• Conn. Cities' Insulin Pricing Suits Against PBMs Join NJ MDL
• Second 'Drugs Made In America' SPAC Raises $500M In IPO
• NY Appeals Court Backs Drug Co.'s $6.5M Contract Case Win
• Omnicare Can Tap $25M Initial DIP, Stage Set For Gov't Feud
• Arcturus Sues AbbVie, Capstan Alleging Trade Secret Theft
• USPTO's Track One A Reliable Patent Pathway Amid Backlog
• Minn. Justices Reject Humana's Pharmacy Sourcing Appeal
• 9th Circ. Allows One More Go-Round In Kleenex Ad Fight
• Vanda Ruling Opens Door For Contesting FDA Drug Denials
• ITC's IP Cases Mainly Target Computer And Telecom Products
• Blank Rome Hires Bicoastal Pair Of Patent Attys
• Law School's Missed Lessons: Mastering Time Management
• Labcorp, Natera Resolve DNA Sequencing IP Suits Midtrial
• PE-Focused Debt Finance Pro Boosts Cooley's Boston Office
• UC Researchers Win Expanded Injunction Against Grant Cuts
• OTC Drug Co. Must Face Shampoo Cancer Risk Class Action
• CBP Says It Didn't Coordinate With Apple In Import Ban Case
• Eli Lilly Deal In Weight Loss Drugs Trademark Suit Hits Snag
• Google, Meta Beat BlueChew Users' Privacy Suit, For Now
• Stem Cell Co. Beats Investor Suit Over Failed Janssen Collab
• This Week In Healthcare Cybersecurity
• Axsome Settles Investors' Drug Approval Suit For $7.8M
• Fed. Circ. Gives Bayer Chance To Save Xarelto Patent Claims
• Tylenol MDL In Spotlight After Trump Blasts Use In Pregnancy
• How Attys Are Riding The Mass. Biotech 'Roller Coaster'
• NC Sens. Vote To Cut Planned Parenthood's Medicaid Funds
• Pfizer Settles Conn. Zantac Lawsuits Alleging Cancer Risks
• EX-CTA Worker's $425K Vaccine Bias Award Capped At $300K
• Two Longtime HHS Attys Depart Posts For Crowell & Moring
• Foley & Lardner Adds Healthcare Deals Pro From Holland & Knight
• HealthTrackRx Names 2nd Chief Legal Officer In 2025
• Rare Del. Oversight Ruling Sends Governance Wake-Up Call
• How Hyperlinks Are Changing E-Discovery Responsibilities
• 5th Circ.'s 340B Ruling 'Limited,' Pharma Cos. Tell 4th Circ.
• In-House Judge Won't Pause FTC's Heart Valve Deal Challenge
• J&J Ruling Misapplied Goldman Precedent, 3rd Circ. Told
• Pharma Copay Programs Raise Complex Economic Questions
• Catching Up With Delaware's Chancery Court
• State False Claims Acts Can Help Curb Opioid Fund Fraud
• CVS's Omnicare Hits Ch. 11 After $949M FCA Judgment
• Wachtell, Paul Weiss Advise On Pfizer's $7.3B Obesity Path
• ProPhase COVID-19 Testing Units Hit Ch. 11 In NJ
• Chinese Exec Who Shipped Fentanyl Ingredients Gets 25 Yrs
• Stewart Issues Mixed Bag Of Referrals, Denied Petitions
• Call For Gov't Cut Of University Patent Cash Spurs Concern
• Goodwin, Latham Steer E-Commerce Co. Pattern's $300M IPO
• PTAB Invalidates Johns Hopkins Patent In Keytruda Fight
• Beaming Up Lessons From William Shatner's Failed Patent Bid
• DA In Gilgo Beach Killings Case Talks Advances In DNA Use
• Moderna Wants Fed. Circ. Reversal Of Vax Patent Invalidation
• Rite Aid Gets OK To Seek Votes On Dual-Track Ch. 11 Plan
• CDC Panel Urges Caution On COVID Vax, Punts On Hep B
• Federal Vaccine Panel Votes To Tweak MMRV Recommendation
• Cytokinetics Investor Sues Over Heart Drug Approval Claims
• Brothers Blame Associate For $90M HIV Drug Fraud Scheme
• HHS Shutters Miami Organ Donor Org. For 'Unsafe' Practices
• Senate Confirms Squires To Lead USPTO
• Senate Confirms Trump's Pick To Lead DOL Benefits Arm
• Steptoe Adds Jones Day Biotech Patent Pro To NY Office
• Colibri Wants Full Fed. Circ. To Rethink Medtronic Patent Case
• The Pros And Cons Of Levying Value-Based Fees On Patents
• NJ City Makes 3rd Escape From Pot Co.'s Zoning Suit
• Dorsey & Whitney IP Atty Joins Foley Hoag In Denver
• Montreal-Based Corp. Atty Moves To Akerman's NY Office
• Japanese Glycine Exporter Hit With 86% Antidumping Duty
• Group Of US Investors To Buy TikTok, Plus More Rumors
• Valitic Soap Is Unapproved Drug, Class Of Buyers Claims
• Writing Musicals Makes Me A Better Lawyer
• J&J Whistleblowers Defend $1.6B False Claims Act Win
• Chancery Mulls Limited Discovery In $8.7B Cerevel Sale Suit
• FDA Says Vape Manufacturer Lying About Marketing Approval
• Don Jr.-Backed Patent Co. Hires Nokia Licensing Exec
• Missouri AG Can Seek Unredacted Trans Care Records
• Between The Lines Of EPO's Adoption Of Color Drawings
• What Prop 65 Ruling Means For Cosmetics, Personal Care Biz
• Ex-CDC Head Says RFK Jr. Urged Vax Schedule Rubber Stamp
• Purdue Can Pay CEO Ch. 11 Bonus After Trimming Comp
• Adapting To Private Practice: From Va. AUSA To Mid-Law
• Exactech Enters $8M Deal To Resolve Implant Failure Claims
• Merck Says Vaccine Case 'Poor Vehicle' For Antitrust Review
• BrainStorm Can't Shed Investors' ALS Treatment Trial Claims
• 2 Fed. Circ. Rulings Underscore Patent Prosecution Pitfalls
• The Patent Workforce Is Attracting Fewer Attys, More Agents
• Jazz Can't Escape Antitrust Claims Over Sleep Disorder IP
• CVS Caremark Takes $290M Overbilling Judgment To 3rd Circ.
• FTC Chair Pledges 'Action' Against Late Merger Fixes
• Rebutting Price Impact In Securities Class Actions
• Jones Day Adds FDA Regulatory Expert As Of Counsel In DC
• 7 Document Review Concepts New Attorneys Need To Know
• For Cahill Atty, Rare Disease Pro Bono Work Is Personal
• VarmX Partners With Biotech CSL In Deal Worth Up To $2.2B
• Ruling On Labor Peace Law Marks Shift For Cannabis Cos.
• Jazz Loses Bid To Block Avadel From Seeking Sleep Drug OK
• AbbVie Settles Rinvoq Litigation, Blocks Generics Until 2037
• Ch. 11 Plan Faces Blowback From 23andMe Breach Claimants
• Bayer Urges 9th Circ. Not To Revive Tevra Flea, Tick Meds Suit
• Ex-PTAB Leader Reflects On USPTO After Leaving Agency
• Investor Says $16M Ouraring Fight Shouldn't Go To Finland
• Stewart Says New Policies Seek Fairness For Patent Owners
• Eli Lilly Fights $278M Drug Royalties Ruling At 9th Circ.
• Corcept Can't Escape Teva's Mifepristone Antitrust Suit
• Fed. Circ. Rulings Refine Patent Claim Construction Standards
• Exactech Gets OK For Ch. 11 Plan Ditching Sponsor Deal
• Novartis, Monte Rosa Ink Up To $5.7B 'Molecular Glue' Deal
• Ex-Investor Relations Exec Gets 15 Months For Inside Trades
• AbbVie Can't Halt Miss. Discount Drug Law, 5th Circ. Says
• Stewart Issues New Slate Of Discretionary Denials
• 23AndMe Inks $3.25M Data Breach Deal With Canadian Users
• Jury Awards Mallinckrodt $9.5M In Nitric Oxide Patent Suit
• Novartis Takes Entresto Bench Trial Loss To Fed. Circ.
• US Sprinter Gets 4-Year Doping Ban Despite Oxtail Defense
• Saudi Blockade Leads To $100M Award To Qatar Pharma Co.
• How Value-Based Patent Fees May Shape IP Strategies
• Boehringer Misused Forfeited Retirement Funds, Suit Says
• Agentic AI Puts A New Twist On Attorney Ethics Obligations
• Ex-Conn. Assistant AG Faces DQ Bid In Price-Fixing Case
• UK Litigation Roundup: Here's What You Missed In London
• States Push Conn. Court To Ban Generic Drug Price-Fixing
• 9th Circ. Says News Article Doesn't Doom Biotronik FCA Suit
• Medicare Drug Pricing Plan Survives Novartis' 3rd Circ. Appeal
• 2 NY Fertility Clinics Must Face Suit Over Destroyed Eggs
• Industrial Tech Co. Sanctioned For Deleted Texts In Title VII Suit
• 1st Circ. OKs Freeze Of Planned Parenthood Medicaid Funding
• Ex-USPTO Solicitor Says Squires Is Better Than No One
• Insulin Makers Ask 2nd Circ. To Rethink Collusion Claims
• 3rd Circ. Won't Toss Talc Co. Whittaker Clark & Daniels' Ch. 11
• 7th Circ. Backs $183M FCA Award Over Eli Lilly Drug Rebates
• Dental Supply Co.'s $84M Price-Fixing Deal Gets Final OK
• Using Reissue Applications To Strategically Improve Patents
• Freshfields, Kirkland Advise On Advent's $4.7B Zentiva Sale
• FDA Transparency Plans Raise Investor Disclosure Red Flags
• Zeiss Secures $785K In X-Ray Patent Trial Against Sigray
• Cooley-Led LB Pharmaceuticals Raises Upsized $285M IPO
• Being A Professional Wrestler Makes Me A Better Lawyer
• Fed. Circ. Won't Revisit Double-Patenting, Soda TM Appeals
• Teleradiology Co. Seeks OK Of Award Nixing $2M Fraud Claim
• DexCom Beats Most Of Investors' Diabetes Device Sales Suit
• Hydroxycut Maker Iovate Gets Ch. 15 Relief As Case Kicks Off
• Chemical Co. Challenges $7.7M Tax Bill Over Foreign Credits
• Patent Claim Lessons From Fed. Circ.'s Teva Decision
• Medical Equipment Co. Settles County Claims In Opioid MDL
• Jones Day Adds Ex Fed. Prosecutor To SF Healthcare Team
• Law School's Missed Lessons: Adapting To The Age Of AI
• Chinese Scholar Gets Time Served In Smuggling Case
• Splenda Maker Says Scientist's Counterclaims Are Too Late
• Ch. 11 Ruling Voiding $2M Litigation Funding Sends A Warning
• 4th Circ. Debates Whether 'Silence' In 340B Empowers States
• CVS Says Takeda Tried To Block Heartburn Drug Competition
• PTAB Leader Urges Specificity In Discretionary Denial Briefs
• Zantac Buyers Will Appeal Sanofi Dismissal From Conn. Suit
• Omni Must Pay Atty Fees Over 'Troubling' Conduct In FCA Suit
• MAHA Report Calls For Increased Scrutiny Of Drug Advertising
• Gilgo Beach DNA Evidence Ruling May Propel New Methods
• Sandoz, Regeneron Settle Eye Drug Patent Claims
• Particle's Antitrust Battle With Epic: 3 Things To Know
• DOJ's Novel Cybersecurity FCA Case Is A Warning To Medtech
• Roberts Pauses Foreign Aid Distribution For Now
• Future-Proof Patent Law By Starting Talent Pipelines Early
• Kidney Care Co. Strive Health Secures $550M In New Funding
• DOJ, FTC Urged To Probe Drugmakers' Rebate Models
• 3rd Circ. Told Cigna's 'Private Label' Stelara May Alter Market
• Demystifying The Civil Procedure Rules Amendment Process
• NY AG To Fight Texas Bid To Enforce Abortion Ban Ruling
• Oura Domestic Labor Investment Won Import Ban, ITC Says
• FisherBroyles Can't Nix Stem Cell Patent Malpractice Claim
• Whisper Not Enough To Sustain Worker's Harassment Suit
• How USPTO Examiner Memo Informs Software Patent Drafting
• Trump Returns To High Court In Foreign Aid Freeze Dispute
• FibroGen To Pay SEC $1.25M Over Drug Mistatements
• Catching Up With Delaware's Chancery Court
• 23andMe's Ch. 11 Sale Flouted State Privacy Law, Calif. Says
• DC Circ. Won't Halt Order Releasing Billions In Foreign Aid
• Stewart Tackles Markets, Injunctions In Newest PTAB Reviews
• Federal Agencies Push To Toss Masimo's Apple Watch Suit
• 2nd Circ. Backs Ex-Pfizer Worker's Insider Trading Conviction
• DOJ Pushes To DQ Attorney Over Conflict In Fraud Case
• Merck Shakes Off Some Claims From Cholesterol Drugs Suit
• Vein Tech Maker Wants Suit Over DOJ Kickback Probe Tossed
• FDA Explains Rejection Of MDMA Therapy For Treating PTSD
• Casper Can't Escape Innovator-Liability Drug Label Suit
• How 2nd Circ. Cannabis Ruling Upends NY Licensing
• Conn. Biotech Hits Ch. 11 With $2.7M Debt After Patent Suit
• Motley Rice Fights OptumRx DQ Bid In Utah Opioid Suit
• Parenting Skills That Can Help Lawyers Thrive Professionally
• Enablement Standard Insights From Fed. Circ. Agilent Ruling
• Feds Seek Stay On Court Order Releasing Foreign Aid Billions
• Split 3rd Circ. Rejects Janssen, Bristol Myers Pricing Appeal
• Doc Tells 1st Circ. Acquitted Conduct Marred Drug Sentence
• 4th Circ. Affirms Gardasil's Vaccine Table Inclusion
• Generic Drug Org Backs MSN In High Court Entresto Appeal
• GSK Adds Moderna's New COVID Vaccine To Del. IP Suit
• Why The Harvard Funding Case Is 'Clear As Mud' On Appeal
• Sterne Kessler Adds Ex-Deputy Chief PTAB Judge
• DOJ Moves To End Challenge To RFK Jr.'s Vaccine Directive
• Monthly Merger Review Snapshot
• Robitussin Maker Must Face Woman's Lung Infection Suit
• PBMs Look To Toss FTC's Insulin Pricing Case
• RFK Renews Attacks On CDC At Fiery Capitol Hill Appearance
• 3rd Circ. Preview: Sept. Features Biosimilars, Gambling Cases
• Teaching Trial Advocacy Makes Us Better Lawyers
• The Crucial Question Left Unanswered In EpicentRx Decision
• Sanofi Settles Conn. Zantac Suits Alleging Cancer Risks
• Purdue Pharma Approved For $17.5M In Ch. 11 Bonus Plans
• Ohio Cannabis Card Network Sued Over Faulty Cybersecurity
• 7th Circ. Backs AbbVie's Win Against Ex-Sales Rep's FCA Suit
• 9th Circ. Won't Revive Genentech Ex-Worker's 401(k) Suit
• Federal AI Action Plan Marks A Shift For Health And Bio Fields
• Fla. Surgeon General Pushes To End State's Vaccine Mandates
• Judge Backs Harvard In Suit Over Trump's $2B Fund Freeze
• Novartis Inks Up To $5.2B Deal With Chinese Cardio Biotech
• NC Panel Revives Biotech Co.'s Legal Malpractice Case
• Insurer Escapes Duty To Cover Lab's Suit Over COVID Tests
• Preparing For DEA Rescheduling Of 2 Research Chemicals
• Why EpicentRx Ruling Is A Major Win For Business Certainty
• Judge Accepts DNA Evidence In Gilgo Beach Case
• Auto Injection, Ypsomed Settle Insulin Pen Patent Dispute
• Speculation Can't Halt Medical Coatings Merger, GTCR Says
• $33M Pfizer Antitrust Deal OK'd, First MDL Trial Date Set
• Confusion Over Slashed Patent Verdict Vexes Fed. Circ. Judge
• Ex-Executive Slaps Novo Nordisk Unit With Sex, Age Bias Suit
• Jury Clears Exela In Blood Pressure Drug Patent Suit
• CooperSurgical Says Earlier Cases Sink Conn. Filshie Clip Suits
• Defective Vascular Port Caused Man's Death, Suit Says
• A Change In Big Pharma Response To FTC Delisting Warnings
• Gilead Rival Agrees Not To Sell Generic HIV Drug For Now
• Post-Ch. 11 Teligent 'Caremark' Suit Moves Forward In Del.
• As Product Recalls Rise, So Do The Stakes For The Bar
• Wells Fargo Employee Drug Cost Battle: What To Know
• Adapting To Private Practice: From Texas AUSA To BigLaw
• 'Never My Intention' To Defy Justices, Judge In NIH Case Says
• HHS Office Of Inspector General Leader Joins Arnold & Porter